Vivimed Labs Ltd Locks at Upper Circuit With 4.9% Gain — Buyers Queue, Sellers Absent

Circuit Event and Unfilled Demand

The stock, trading in the BE series, hit its upper circuit price of Rs 5.99, marking a 4.9% gain within the 5% price band allowed for the day. This ceiling price effectively froze trading at the peak level, signalling that demand exceeded what the price band could accommodate. The total traded volume stood at 1.07 lakh shares, with a turnover of just ₹0.063 crore. The circuit lock means that while buyers were eager to purchase at Rs 5.99, sellers were absent, creating a backlog of unfilled demand. Vivimed Labs Ltd’s session illustrates how the exchange’s price band mechanism can cap gains even amid strong buying interest — what does the full demand picture look like for Vivimed Labs Ltd once the circuit unlocks and normal trading resumes?

Delivery and Volume Analysis

Delivery volumes, a key indicator of buying conviction, tell a more cautious story for this circuit day. On 25 Jun 2026, the last available delivery volume data, shares delivered fell by 15.64% compared to the 5-day average, with only 10,140 shares taken in delivery. This decline suggests that the upper circuit move on 29 Jun may have been driven more by speculative demand or thin liquidity rather than robust long-term accumulation. Volume on a circuit day is mechanically suppressed due to the price lock, but the falling delivery volume raises questions about the sustainability of the buying pressure — is Vivimed Labs Ltd's 4.9% surge backed by improving fundamentals or is this a liquidity-driven micro-cap move?

Moving Averages and Trend Context

Vivimed Labs Ltd closed above its 5-day moving average, signalling short-term strength, but remains below its 20-day, 50-day, 100-day, and 200-day moving averages. This mixed technical picture indicates that while the immediate trend has turned positive, the broader trend remains subdued. The stock’s recent gain follows eight consecutive days of decline, marking a potential trend reversal in the short term. The upper circuit day amplified this recovery, but the failure to clear longer-term moving averages suggests the rally is still in its early stages and may face resistance ahead.

Liquidity and Market Capitalisation Context

With a market capitalisation of approximately ₹47 crore, Vivimed Labs Ltd is classified as a micro-cap stock. Liquidity remains a critical factor here: the stock’s average traded value over five days supports a trade size of effectively ₹0 crore, highlighting extremely limited institutional-grade liquidity. This thin order book means that even modest buying or selling interest can cause outsized price moves, as seen in the upper circuit event. Investors should be mindful that entering or exiting sizeable positions in such a stock can be challenging, and the circuit lock may exaggerate price moves that are not fully supported by broad market participation.

Intraday Price Action

The intraday range for the session was relatively narrow, with a low of Rs 5.51 and a high of Rs 5.99, the circuit price. The stock’s price climbed steadily through the day before hitting the ceiling, where it remained locked. This pattern is typical for circuit hits, where the price range tightens near the upper limit as buyers queue and sellers withdraw. The limited intraday volatility within the band reflects the mechanical constraints imposed by the circuit rather than a lack of interest.

Brief Fundamental Context

Vivimed Labs Ltd operates in the Pharmaceuticals & Drugs industry, a sector known for its cyclical and regulatory sensitivities. While the stock’s recent price action shows a short-term bounce, the fundamental backdrop remains mixed, with no immediate data suggesting a significant shift in earnings or operational performance. The micro-cap status and limited liquidity further complicate the interpretation of price moves, underscoring the importance of cautious analysis.

Conclusion: Circuit, Delivery, and Liquidity Signals

The upper circuit hit at Rs 5.99 capped a 4.9% gain within the 5% price band, locking in gains but also locking out buyers who arrived late. Delivery volumes falling by over 15% against the recent average suggest the move was not strongly supported by long-term accumulation. The stock’s position above the 5-day moving average but below longer-term averages points to a tentative short-term recovery rather than a confirmed uptrend. Crucially, the micro-cap nature and near-zero liquidity mean that price moves can be exaggerated and difficult to trade around. After a 4.9% single-day gain at upper circuit, is Vivimed Labs Ltd still worth considering or has the move already happened? The multi-factor analysis weighs the data.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today